An observational study in Cytomegalovirus Infection and Hematopoietic Stem Cells Transplantation, sponsored by MSD Italia S.r.l.. Recruiting at 5 sites in Italy. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by MSD Italia S.r.l. (part of Merck & Co., Inc) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Cytomegalovirus Infections with a site in Italy — 5 open to participants now, 6 under way, 1 of them phase 3. Cytomegalovirus Infections · Italy.
Among the 18 studies in Cytomegalovirus Infections with a site in Italy, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 17th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →5 of the 18 studies in Cytomegalovirus Infections with a site in Italy are open now. Recruiting first, the newest first:
Antonello Di Paolo, M.D., Ph.D. · Sites in Italy
Ages 1 mo–18 yrs
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy, United States, Belgium and 6 more countries
Ages 18+
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
Tobias Feuchtinger · Sites in Italy, Belgium, France and 3 more countries
Ages 2 mo+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 150 across 93 observational studies indexed under Cytomegalovirus Infections.
Median enrollment 326 across the 14 interventional studies, 177 across the 4 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under MSD Italia S.r.l., one of the names counted as Merck & Co., Inc. Under that name alone:
MSD Italia S.r.l. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Merck & Co., Inc has 8 studies filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Cytomegalovirus Infections with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05234723IRCCS Azienda Ospedaliero-Universitaria di BolognaGanciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Cytomegalovirus Infections with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.
This is an observational retrospective analysis from the main pediatric centers in Italy (approximately 5 sites). The selected sites will be the most representative of Italy because they perform about 2/3 of all allogeneic HSCT per year.
Index date: date of allogeneic HSCT; retrospective data will be captured in consecutive patients undergoing allogeneic HSCT from January 2018 to June 2020 with maximum 12 months of follow-up for each patient. The data of the patients undergoing allogeneic HSCT after June 2020 will not be captured in order to avoid any possible bias due to off-label access to letermovir.
Medical Records (MR) will be used to describe the risk factors, patient characteristics, treatment patterns, and healthcare resource utilization of subjects who had a CMV infection.
Electronic or paper hospital charts (inpatient), clinical charts (inpatient and outpatient), and outpatient records will all be considered as MR for study purposes.
This is a secondary data collection study from electronic or paper medical chart review, no data from registry will be collected.
Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable.
About 230 patients from birth to less than 18 years of age allogeneic HSCT recipients at risk of developing CMV infection and/or disease who underwent allogeneic HSCT between January 2018 and June 2020 in the participating hospitals will be enrolled in the study. The selected hospitals will be the main ones in Italy based on the number of transplants performed every year and also considering the geographical distribution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Summary of demographic and baseline characteristics
Description through frequencies and percentages (for categorical variables) and mean and median values, SD, quartiles, interquartile ranges and extreme values (for continuous variables).
Time frame: at baseline (day of transplant)
CMV Seroprevalence in the under 18 population undergoing allogeneic HSCT
Proportion of patients CMV R+ at transplantation. CMV-seroprevalence and serostatus will be described according to the recipient or donor positivity. Comparisons will be conducted using the Chi-square or Fisher's exact test (for categorical variables), or the t-test or Wilcoxon rank sum test (for continuous variables).
Time frame: at baseline (day of transplant)
CMV serostatus
R+/D-, R+/D+ and R-/D+ combination frequencies. CMV-seroprevalence and serostatus will be described according to the recipient or donor positivity. Comparisons will be conducted using the Chi-square or Fisher's exact test (for categorical variables), or the t-test or Wilcoxon rank sum test (for continuous variables).
Time frame: at baseline (day of transplant)
Donor type
Allogeneic HSCT characteristics
Time frame: at baseline (day of transplant)
Stem cell source
Allogeneic Hematopoietic Stem Cells Transplantation characteristics
Time frame: at baseline (day of transplant)
Conditioning intensity
Allogeneic Hematopoietic Stem Cells Transplantation characteristics
Time frame: at baseline (day of transplant)
Underlying condition
Allogeneic Hematopoietic Stem Cells Transplantation characteristics
Time frame: at baseline (day of transplant)
Usage of immunosuppression
Allogeneic Hematopoietic Stem Cells Transplantation characteristics
Time frame: at baseline (day of transplant)
Current standard of care in CMV management in terms of PET approach
It will be described quantitatively by tabulating frequencies and percentages.
Time frame: during the first-year post-transplant
Current standard of care in CMV management in terms of GCV prophylaxis
It will be described quantitatively by tabulating frequencies and percentages.
Time frame: during the first-year post-transplant
Current standard of care in CMV management in terms of ACV prophylaxis
It will be described quantitatively by tabulating frequencies and percentages.
Time frame: during the first-year post-transplant
Current standard of care in CMV management in terms of other
It will be described quantitatively by tabulating frequencies and percentages.
Time frame: during the first-year post-transplant
Rate of clinically significant CMV infection
Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
Median time to first CS-CMVi
A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.
Time frame: during the first year after transplantation
Rate of viral infections other than CMV
Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
Rate of bacterial infections
Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
Rate of fungal infections
Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
Allogeneic HSCT risk factors
Underlying condition, donor type, stem cell source, conditioning intensity, immunosuppressive therapies. The relation between complications and risk factors will be analyzed through Cox regression models.
Time frame: at baseline (day of transplant)
CMV-related complications
Proportion of patients with at least one CMV disease, "overall" and by type of disease, and number of diseases per patient. The relation between complications and risk factors will be analyzed through Cox regression models.
Time frame: during the first-year post-transplant
CMV-related complications
Rate of acute and chronic Graft vs Host Disease Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
CMV-related complications
Rate of opportunistic infection declared by the investigator "CMV related-complication"
Time frame: during the first-year post-transplant
Number of hospitalizations and length of stay (LOS) after allogeneic HSCT
Utilization of several healthcare resources will be described to quantify the economic burden. Data will include frequency of re-hospitalization, exams, diagnostic tests, visits, drugs use and the duration of re-hospitalization. Statistical tests (Chi-square, Fisher's exact, Student's T or Wilcoxon rank-sum) will be applied based on the variable type.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
All-cause mortality rate
Kaplan-Meier curves will describe the timing of events.
Time frame: at day +100, day +200 and during the first year post allogeneic HCT
Started May 2025 (actual). Primary completion is estimated for Apr 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.